.png){kind=small}
The global cell counting market is estimated to have a substantial growth potential, with revenues expected to increase from $10.4 billion in 2020 to $14.5 billion by 2025, driven by factors such as increased funding for cell-based research, rising disease incidences, and advancements in technology.
Summary
The global cell counting market was valued at $10.4 billion in 2020 and is projected to reach $14.5 billion by 2025, with a compound annual growth rate (CAGR) of 6.7%.
Factors fueling market growth include increased funding for cell-based research, a rising incidence of chronic and infectious diseases, growth in the biotechnology and biopharmaceutical industries, advancements in solutions and image analysis, and increased use of high-throughput flow cytometry and automated hematology analyzers.
The medical application segment is expected to grow at the highest CAGR, with government initiatives in stem cell research and widespread usage of cell counting in research driving growth.
Hospitals and diagnostic laboratories are anticipated to experience the highest CAGR among end users, attributed to regulatory approvals for cell culture-based vaccines, increased pharmaceutical research and development expenditure, and commercial expansion by pharmaceutical companies.
The Asia Pacific region is expected to dominate the cell counting market due to growing proteomics, genomics, stem cell research activities, increased research funding, investments by pharmaceutical and biotechnology companies, and modernization of research infrastructure.
Major companies in the cell counting market include Danaher Corporation, Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Merck KGaA, and Bio-Rad Laboratories.
The report categorizes the market based on product, application, end user, and region, offering insights into segments like consumables, instruments, research applications, cancer research, immunology research, and more.
Recent developments in the market include Danaher's acquisition of the Biopharma business of GE Life Sciences, Agilent Technologies' acquisition of BioTek Instruments, and Perkin Elmer's partnership with Accenture to accelerate drug discovery.
For further information, you can visit the original web page.